BioSpace News Archive

Surrozen, Inc. (Nasdaq: SRZN), a company pioneering targeted therapeutics that selectively activate the Wnt pathway for tissue repair and regeneration, announced today that a poster supporting the potential of SZN-413 for the treatment of diabetic retinopathy was presented on May 1 at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting in Denver.

Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company committed to transforming the care of people living with rare genetic diseases of obesity, today announced the presentation of new data supporting the potential for setmelanotide to treat the early-onset obesity, hyperphagia and metabolic impairment associated with Bardet-Biedl syndrome (BBS).

Motus GI Holdings, Inc., (NASDAQ: MOTS) (“Motus GI” or the “Company”), a medical technology company providing endoscopy solutions that improve clinical outcomes and enhance the cost-efficiency associated with the diagnosis and management of gastrointestinal conditions, announced today a poster featuring topline data from the EU study of the Pure-Vu System has been selected to be presented at Digestive Disease Week® (DDW).

Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, will announce its first quarter 2022 financial results prior to market open on Friday, May 6, 2022.

Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today announced that the Company will present five scientific posters at the upcoming 2022 American Thoracic Society (ATS) International Conference.

Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, announces new data validating the benefits of the Company’s BVA-100 blood test (BVA) in improving survival for advanced heart failure patients with left ventricular assist device (LVAD).

Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced the acceptance of an abstract for a poster presentation at the upcoming 2022 American Society of Clinical Oncology (ASCO) Annual Meeting.

DENTSPLY SIRONA Inc. (“Dentsply Sirona”) (Nasdaq: XRAY) today announced that its first quarter 2022 earnings conference call and live webcast will be held on Tuesday, May 10, 2022, at 8:30 am ET.

Medicenna Therapeutics Corp. today announced new clinical data from the Phase 1/2 ABILITY (A Beta-only IL-2 ImmunoTherapY) study of MDNA11, the Company’s long-acting IL-2 super-agonist.

Endo International plc (NASDAQ: ENDP) announced today that its subsidiary Endo Ventures Limited (EVL) acquired six development-stage, ready-to-use injectable product candidates from Nevakar Injectables Inc., a subsidiary of Nevakar, Inc.